CVRx Inc CVRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
-
CVRx Announces Appointment of Two New Board Members
-
Bragar Eagel & Squire, P.C. Is Investigating Arhaus, Cardlytics, and CVRx and Encourages Investors to Contact the Firm
-
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX
-
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of CVRx, Inc. - CVRX
-
CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx, Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the Firm
Trading Information
- Previous Close Price
- $8.53
- Day Range
- $8.46–8.79
- 52-Week Range
- $6.40–33.14
- Bid/Ask
- $8.68 / $8.88
- Market Cap
- $191.28 Mil
- Volume/Avg
- 119,020 / 315,697
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.18
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 200
- Website
- https://www.cvrx.com
Comparables
Valuation
|
Metric
|
CVRX
|
ATEC
|
ANIK
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 80.61 |
Price/Book Value | 3.45 | 45.31 | 1.76 |
Price/Sales | 4.18 | 1.37 | 2.20 |
Price/Cash Flow | — | — | 18.08 |
Price/Earnings
CVRX
ATEC
ANIK
Financial Strength
|
Metric
|
CVRX
|
ATEC
|
ANIK
|
|---|---|---|---|
Quick Ratio | 8.66 | 1.08 | 3.70 |
Current Ratio | 10.08 | 2.22 | 5.93 |
Interest Coverage | −17.10 | −8.06 | — |
Quick Ratio
CVRX
ATEC
ANIK
Profitability
|
Metric
|
CVRX
|
ATEC
|
ANIK
|
|---|---|---|---|
Return on Assets (Normalized) | −38.15% | −9.32% | 2.40% |
Return on Equity (Normalized) | −55.52% | −562.13% | 2.97% |
Return on Invested Capital (Normalized) | −39.31% | −8.81% | 1.92% |
Return on Assets
CVRX
ATEC
ANIK
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Vbycvrqp | Zcnfnf | $196.0 Bil | |||
| Stryker Corp
SYK
| Kzsprlmyp | Qdpm | $133.8 Bil | |||
| Boston Scientific Corp
BSX
| Gzrhzshhr | Slzmrm | $124.5 Bil | |||
| Medtronic PLC
MDT
| Zlbljtbjy | Dldsn | $113.2 Bil | |||
| Edwards Lifesciences Corp
EW
| Wtcthglwl | Jchnbxn | $39.5 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Yfp | Hnfsp | $30.2 Bil | |||
| DexCom Inc
DXCM
| Qqrkbvmvxn | Klcm | $27.3 Bil | |||
| Steris PLC
STE
| Smlpdpkz | Knzwbx | $22.8 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Vkmbytwqb | Tylmn | $21.3 Bil | |||
| Insulet Corp
PODD
| Gxklgcct | Ymvvtr | $16.1 Bil |
United States